Key result
Lower sKlotho is linked to increased Ao-PWV in patients with T2D and early DKD.
Why the study?
The relationship between circulating antiaging hormone sKlotho and aortic pulse wave velocity in diabetic kidney disease was unknown.
Are reduced levels of sKlotho associated with increased aortic stiffness in patients with type 2 diabetes and early stage diabetic kidney disease?
Cross-Sectional (n=172)
Are reduced levels of sKlotho associated with increased aortic stiffness in patients with type 2 diabetes and early stage diabetic kidney disease?
Lower levels of the antiaging hormone sKlotho are independently associated with increased aortic stiffness in patients with type 2 diabetes and early diabetic kidney disease, suggesting a potential mechanism for enhanced cardiorenal risk.
Hypothesis-generating for sKlotho as aortic stiffness biomarker; leaves open causal role or therapeutic targeting in diabetic kidney disease.
Introduction Aortic pulse wave velocity (Ao-PWV) predicts cardiovascular and kidney disease in type 2 diabetes (T2D). Klotho is a circulating antiaging hormone (sKlotho) with putative cardiorenal protective effects. The relationship between sKlotho and Ao-PWV in diabetic kidney disease (DKD) is unknown. Methods In a cross-sectional cohort study, the correlation of sKlotho measured by a validated immunoassay, and Ao-PWV measured by applanation tonometry, was investigated in 172 participants with T2D and early stage DKD (all had estimated glomerular filtration rate [eGFR] >45 ml/min) on stable renin angiotensin system (RAS) inhibition. In cultured human aortic smooth muscle cells (HASMCs) stimulated with angiotensin II (AngII), the effects of recombinant human sKlotho pretreatment were assessed on intracellular calcium ([Ca 2+ ] i ) responses and expression of proteins associated with proosteogenic HASMC phenotypes. Results Mean (range) age of the cohort was 61.3 years (40–82) and 65% were male. Mean (±SD) Ao-PWV was 11.4 (±2.3) m/s, eGFR 78.8 (±23.5) and median (interquartile range) sKlotho of 358.5 (194.2–706.3) pg/ml. In multivariable linear regression analyses, we observed a statistically significant inverse relationship between sKlotho and Ao-PWV, which was independent of clinical risk factors for cardiorenal disease. Pretreatment of cultured HASMC with sKlotho significantly attenuated AngII-stimulated [Ca 2+ ] i transients and reduced osteogenic collagen (Col1a2) expression. Conclusions In individuals with T2D and early DKD, lower levels of sKlotho are associated with increased Ao-PWV. Taken together with the direct effect of sKlotho on mediators of aortic wall stiffness in vitro , these findings may explain the enhanced risk of cardiorenal disease in DKD.
No takes yet. Share an insight, caveat, or question.
Fountoulakis et al. (2023) conducted a cross-sectional in Type 2 diabetes and early stage diabetic kidney disease (n=172). sKlotho levels was evaluated on Aortic pulse wave velocity (Ao-PWV). Lower levels of sKlotho (median 358.5 pg/ml) were significantly associated with increased aortic pulse wave velocity (mean 11.4 m/s) in patients with type 2 diabetes and early diabetic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: